Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X about a recent article by Prof. Eishi Baba et al., published in ESMO OPEN:
“Pembrolizumab vs FTD/TPI (± bev) vs rego in MSS, TMB-H mCRC: Insights from the nationwide C-CAT database OS: 5.4 vs 13.8 vs 15.0m TTF: 1.6 vs 4.1 vs 2.9m For later-line therapy in MSS, TMB-H mCRC, FTD/TPI or rego are preferable options.”
Title: Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes
Authors: K. Yamaguchi, K. Tsuchihashi, S. Ueno, K. Uehara, R. Taguchi, M. Ito, T. Isobe, T. Imajima, T. Kitazono, K. Tanoue, K. Tanoue, K. Akashi, E. Baba
He also shared another article by Dr. Nakamura in this post:
“Our former colleague, Dr. Nakamura, presented a phase 2 study of nivolumab for plasma TMB-H GI cancers at #GI24 Response in 3 of 27 CRC with pTMB-H Breakdown of the 3 responders: MSI-H (1), POLE (2) No responders in remaining 24 CRC with pTMB-H”
Title: Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial
Authors: Yoshiaki Nakamura, Taito Esaki, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Eiji Shinozaki, Hiroya Taniguchi, Takeshi Kato, Ken Kato, Shogo Nomura, Takashi Ikeno, Yukiko Ishiguro, Koji Takahashi, Tsukiko Higuchi, Akihiro Sato, Justin Iver Odegaard, Takeshi Kuwata, Kouji Matsushima, Tetsuya Nakatsura, and Takayuki Yoshino.
More posts featuring Daisuke Kotani.